<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicina (Kaunas)</journal-id><journal-id journal-id-type="iso-abbrev">Medicina (Kaunas)</journal-id><journal-id journal-id-type="pmc-domain-id">3494</journal-id><journal-id journal-id-type="pmc-domain">medicina</journal-id><journal-id journal-id-type="publisher-id">medicina</journal-id><journal-title-group><journal-title>Medicina</journal-title></journal-title-group><issn pub-type="ppub">1010-660X</issn><issn pub-type="epub">1648-9144</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9414636</article-id><article-id pub-id-type="pmcid-ver">PMC9414636.1</article-id><article-id pub-id-type="pmcaid">9414636</article-id><article-id pub-id-type="pmcaiid">9414636</article-id><article-id pub-id-type="pmid">36013498</article-id><article-id pub-id-type="doi">10.3390/medicina58081031</article-id><article-id pub-id-type="publisher-id">medicina-58-01031</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Aqueous Humour Ofloxacin Concentration after Topical Instillation in Patients with Dry Eye Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6648-8921</contrib-id><name name-style="western"><surname>Kagkelaris</surname><given-names initials="K">Konstantinos</given-names></name><xref rid="af1-medicina-58-01031" ref-type="aff">1</xref><xref rid="af2-medicina-58-01031" ref-type="aff">2</xref><xref rid="c1-medicina-58-01031" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>El Mubarak</surname><given-names initials="MA">Mohamed A.</given-names></name><xref rid="af3-medicina-58-01031" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Plotas</surname><given-names initials="P">Panagiotis</given-names></name><xref rid="af4-medicina-58-01031" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Panaretos</surname><given-names initials="D">Dimitris</given-names></name><xref rid="af5-medicina-58-01031" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Panayiotakopoulos</surname><given-names initials="GD">George D.</given-names></name><xref rid="af2-medicina-58-01031" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sivolapenko</surname><given-names initials="GB">Gregory B.</given-names></name><xref rid="af3-medicina-58-01031" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5646-1370</contrib-id><name name-style="western"><surname>Georgakopoulos</surname><given-names initials="CD">Constantinos D.</given-names></name><xref rid="af1-medicina-58-01031" ref-type="aff">1</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Roshandel</surname><given-names initials="D">Danial</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Baradaran-Rafii</surname><given-names initials="A">Alireza</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-medicina-58-01031"><label>1</label>Department of Ophthalmology, School of Medicine, University of Patras, 26504 Patras, Greece; <email>cgeorg@upatras.gr</email></aff><aff id="af2-medicina-58-01031"><label>2</label>Pharmacology Laboratory, School of Medicine, University of Patras, 26504 Patras, Greece; <email>gpanayiotakopoulos@hotmail.com</email></aff><aff id="af3-medicina-58-01031"><label>3</label>Laboratory of Pharmacokinetics, Department of Pharmacy, University of Patras, 26504 Patras, Greece; <email>sheikho@upatras.gr</email> (M.A.E.M.); <email>gsivolap@upatras.gr</email> (G.B.S.)</aff><aff id="af4-medicina-58-01031"><label>4</label>Lab Primary Health Care, School of Health Rehabilitation Sciences, University of Patras, 26504 Patras, Greece; <email>pplotas@upatras.gr</email></aff><aff id="af5-medicina-58-01031"><label>5</label>Laboratory of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece; <email>dimitrispanaretos@hotmail.com</email></aff><author-notes><corresp id="c1-medicina-58-01031"><label>*</label>Correspondence: <email>kostkagk@upatras.gr</email></corresp></author-notes><pub-date pub-type="epub"><day>01</day><month>8</month><year>2022</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2022</year></pub-date><volume>58</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">413360</issue-id><elocation-id>1031</elocation-id><history><date date-type="received"><day>13</day><month>6</month><year>2022</year></date><date date-type="accepted"><day>28</day><month>7</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>08</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>27</day><month>08</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2022-08-29 06:18:20.157"><day>29</day><month>08</month><year>2022</year></date></event></pub-history><permissions><copyright-statement>&#169; 2022 by the authors.</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="medicina-58-01031.pdf"/><abstract><p><italic toggle="yes">Background and Objectives</italic>: A prospective, randomized clinical trial was conducted to evaluate the concentration of ofloxacin in the aqueous humour (AqH) of patients suffering from dry eye disease (DED) after topical instillation. <italic toggle="yes">Materials and Methods</italic>: Ninety-one (91) cataract patients scheduled for phacoemulsification were categorized into three groups according to DED severity. Group I (<italic toggle="yes">n</italic> = 17) was comprised of subjects without DED, patients in group II (<italic toggle="yes">n</italic> = 37) were evaluated as having non-severe DED, while group III (<italic toggle="yes">n</italic> = 37) consisted of patients suffering from severe DED. Preoperatively, patients received 4 drops of 0.3% of ofloxacin at 15 min intervals. One hour after the last instillation, aqueous samples were collected intraoperatively. <italic toggle="yes">Results</italic>: The median AqH concentration of ofloxacin in group I was 199.9 ng/mL (range 92.2&#8211;442.8 ng/mL), while in group II it was 530.5 ng/mL (range 283.7&#8211;1004.9 ng/mL), and 719.2 ng/mL (range 358.0&#8211;1512.4 ng/mL) in Group III, <italic toggle="yes">p</italic> &lt; 0.001 (Kruskal-Wallis tests). Pairwise tests (two-tailed with Bonferroni corrections) between groups resulted in a <italic toggle="yes">p</italic>-value of 0.001 when group II was compared to group I and group III was compared to group I, and a <italic toggle="yes">p</italic>-value of 0.020 when group II was compared to group III. The severity of DED, across groups I, II, and III, and the levels of ofloxacin revealed a strong positive correlation (r = 0.639, <italic toggle="yes">p</italic> &lt; 0.001). <italic toggle="yes">Conclusions</italic>: Ofloxacin concentration in the AqH after topical drop instillation may be affected by the degree of ocular surface inflammation in patients suffering from DED.</p></abstract><kwd-group><kwd>dry eye disease</kwd><kwd>ofloxacin</kwd><kwd>aqueous humor concentration</kwd><kwd>topical instillation</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-medicina-58-01031"><title>1. Introduction</title><p>Dry eye disease (DED) is a complex multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film and accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles [<xref rid="B1-medicina-58-01031" ref-type="bibr">1</xref>]. It has globally evolved into a public health concern, and it shows increasing prevalence worldwide. Hyperosmolarity of the tear film initiates a vicious inflammatory cycle which finally leads to the disruption of the ocular surface. In particular, this leads to apoptosis of the conjunctival epithelial cells, cell membrane damage, a reduction in superficial corneal microvilli, corneal epithelia cell loss, and the disruption of intercellular tight junctions, resulting in corneal epithelial barrier dysfunction [<xref rid="B2-medicina-58-01031" ref-type="bibr">2</xref>,<xref rid="B3-medicina-58-01031" ref-type="bibr">3</xref>,<xref rid="B4-medicina-58-01031" ref-type="bibr">4</xref>,<xref rid="B5-medicina-58-01031" ref-type="bibr">5</xref>,<xref rid="B6-medicina-58-01031" ref-type="bibr">6</xref>,<xref rid="B7-medicina-58-01031" ref-type="bibr">7</xref>]. The resolution of the inflammation is controlled by immunoregulatory processes, but when these fail, the disease becomes amplified resulting in further damage to the ocular surface [<xref rid="B3-medicina-58-01031" ref-type="bibr">3</xref>].</p><p>Ocular surface integrity is essential to attain clinically adequate drug levels following topical administration. Drug penetration into the anterior chamber (A/C) is mainly facilitated through the cornea (the corneal route), which acts as a rate-limiting barrier to drug diffusion due to its anatomy. Owning to its tight junctions and desmosomes, the epithelium poses greater resistance to permeation, mainly to hydrophilic drugs (molecular weight up to 300 Da) that cross it through the intercellular space between its cells (called the paracellular route). Hydrophobic molecules (molecular weight up to 600 Da), due to their ability to partition into the cell membranes, can transverse through the paracellular and intercellular pathways to access the underlying stroma. Microvilli of the apical surface extend the available area for drug absorption. The stromal layer acts as a barrier for hydrophobic molecules, whereas it allows the permeation of hydrophilic molecules. The endothelium also consists of cells linked with tight junctions, but it poses considerably less resistance to drug diffusion [<xref rid="B8-medicina-58-01031" ref-type="bibr">8</xref>,<xref rid="B9-medicina-58-01031" ref-type="bibr">9</xref>,<xref rid="B10-medicina-58-01031" ref-type="bibr">10</xref>]. Instilled drugs are also absorbed through the conjunctiva. Its epithelium holds tight junctions to limit the permeability of high molecular weight drugs. Underlying lymphatics and blood vessels mainly remove the drug from the systemic circulation, reducing its bioavailability in the A/C [<xref rid="B11-medicina-58-01031" ref-type="bibr">11</xref>,<xref rid="B12-medicina-58-01031" ref-type="bibr">12</xref>].</p><p>Ofloxacin is a second-generation fluoroquinolone antibiotic that exhibits a wide range of antimicrobial activity and is commonly applied, pre- and/or post-operatively to avoid the deleterious effects of infectious endophthalmitis and numerous infectious ocular diseases [<xref rid="B13-medicina-58-01031" ref-type="bibr">13</xref>,<xref rid="B14-medicina-58-01031" ref-type="bibr">14</xref>]. Its molecular weight is 361.4 Da and its logK<sub>ow</sub> is &#8722;0.48 (pH 7.2), rendering the molecule slightly hydrophilic in neutral pH, as the tears are [<xref rid="B15-medicina-58-01031" ref-type="bibr">15</xref>,<xref rid="B16-medicina-58-01031" ref-type="bibr">16</xref>]. In light of the increasing resistance of microbes, especially against older and widely used antibiotics, continuous surveillance is an essential measure to take in evidence-based therapeutic prophylaxis and the treatment of infectious diseases [<xref rid="B17-medicina-58-01031" ref-type="bibr">17</xref>,<xref rid="B18-medicina-58-01031" ref-type="bibr">18</xref>]. The choice of antibacterial agents needs to be adapted according to the offending bacteria and the site of infection. The drug&#8217;s ability to achieve a therapeutic level is affected by physiological and pathophysiological factors [<xref rid="B19-medicina-58-01031" ref-type="bibr">19</xref>,<xref rid="B20-medicina-58-01031" ref-type="bibr">20</xref>].</p><p>Given the inflammation and disruption of the ocular surface due to DED, the current study aimed to evaluate the levels of ofloxacin in the aqueous humour (AqH) of patients suffering from severe and non-severe DED after topical instillation.</p></sec><sec id="sec2-medicina-58-01031"><title>2. Materials and Methods</title><p>Ninety-one Caucasian patients scheduled to undergo cataract surgery were studied. Patients were categorized into three groups according to DED severity [<xref rid="B21-medicina-58-01031" ref-type="bibr">21</xref>]. Group I was comprised of 17 subjects without DED (8 male, 9 female, mean age &#177; SD of 71.2 &#177; 8.5 years), group II consisted of 37 patients (19 male, 18 female, mean age 71.5 &#177; 8.3 years) evaluated as having non-severe (mild/moderate) DED, and group III consisted of 37 patients (20 male, 17 female, mean age 77.3 &#177; 7.7 years) suffering from severe DED. Patients with chronic topical ocular treatment, the presence of exfoliation material within the anterior segment of the eye, pigment dispersion syndrome, corneal guttata, A/C angle &lt; 20&#176;, ocular pathologies other than cataract, abnormal eyelid function, diabetes mellitus, renal or hepatic failure, other local and systematic antibiotic treatment, allergy to fluoroquinolone antibiotics, or contact lens use were excluded from the study. The study was approved by the ethics committee of the University of Patras for human research and adhered to the tenets of the Declaration of Helsinki and the ICH-Good Clinical Practice guidelines. Written informed consent was obtained from all the study subjects before inclusion in the study (ClinicalTrials.gov ID: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05213156">NCT05213156</ext-link>).</p><p>One day prior to cataract surgery, during standard cataract preoperative evaluation [<xref rid="B22-medicina-58-01031" ref-type="bibr">22</xref>], all patients were clinically examined, and the severity of DED was determined in accordance with the algorithm proposed by Baudouin et al. [<xref rid="B21-medicina-58-01031" ref-type="bibr">21</xref>]. A brief symptom-based assessment was delivered by scoring the Ocular Surface Disease Index (OSDI) questionnaire, and an evaluation of ocular surface damage was performed through corneal fluorescein staining using the Oxford scale.</p><p>Before surgery, patients received one drop of commercially available topical ofloxacin solution 0.3% (pH 6.4) at monodoses without preservatives (Oxatrex, Zwitter Pharmaceuticals, Athens, Greece), 4 times at 15 min intervals starting 2 h before surgery. The eye drops were applied to the inferior lower fornix. Patients who missed any of the four doses were excluded from the study. Before the administration of ofloxacin drops, patients were instilled one drop of commercially available phenylephrine 10% (Phenylephrine, Cooper S.A. Pharmaceuticals, Athens, Greece) and one drop of commercially available tropicamide 0.5% (Tropixal, DEMO S.A. Pharmaceuticals, Kryoneri, Greece) 3 times every 20 min. Aqueous humor was collected 1 h after the last administration, intraoperatively, at the beginning of cataract surgery.</p><p>Lids, eyelashes, the skin surrounding the globe, and eyelashes were cleaned with 5% povidone-iodine immediately before the operation. A paracentesis track was made with a 15&#176; superblade. A 30 G cannula connected to a tuberculin syringe was inserted into the A/C, and approximately 50 &#956;L of aqueous humor was withdrawn. AqH samples were collected in Eppendorf tubes and immediately placed on ice and protected from light until analysis. Within 1 h, all samples were frozen at &#8722;20 &#176;C.</p><p>Ofloxacin concentrations were determined by HPLC&#8211;MS/MS, as described by El Mubarak et al. [<xref rid="B23-medicina-58-01031" ref-type="bibr">23</xref>]. The HPLC&#8211;MS/MS analysis was performed according to Good Laboratory Practice guidelines and validated according to FDA and EMEA guidelines [<xref rid="B24-medicina-58-01031" ref-type="bibr">24</xref>,<xref rid="B25-medicina-58-01031" ref-type="bibr">25</xref>]. Concisely, AqH samples were vortexed, and 30 &#956;L was reconstituted with 10 &#956;L of internal standard (ciprofloxacin &#8805; 98%, Merck, Darmstadt, Germany) and 300 &#956;L of acetonitrile (HPLC grade, Sigma-Aldrich, Darmstadt, Germany). Solutions were vortexed for 1 min, centrifuged at 10,000&#215; <italic toggle="yes">g</italic> for 5 min, and the supernatant was dried on a CentriVap cold trap concentrator (Labconco, Kansas City, MO, USA). Dried extracts were reconstituted in 1000 &#956;L of 0.1% formic acid (HPLC grade, Sigma-Aldrich, Germany) in aqueous, filtered through RC 0.22 &#956;m filters (Phenomenex, Torrance, CA, USA), and 50 &#956;L was introduced into Waters HPLC system (Alliance HT 2795), which was equipped with a Micromass Quattro micro tandem MS system (Waters, Milford, MA, USA). A Synergi Hydro-RP column 100 &#215; 2 mm, 4 &#956;m, Proguard, 2 to 8 mm (Phenomenex, Washington, DC, USA) at 40 &#176;C with a mobile phase consisting of 0.1% formic acid in aqueous (Solvent A) and acetonitrile (Solvent B), at a flow rate of 0.3 mL/min, were used. The MS system was set in positive ion mode to operate the electrospray ion source. Its settings were as follows: desolvation temperature, 450 &#176;C; source temperature, 100 &#176;C; desolvation gas flow, 500 L/h; collision gas (argon) flow, 50 L/h; capillary voltage, 3.5 kV, and the multiplier at 650 V; cone voltage, 33 V; collision energy, 16 eV. The selected transitions <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> (multiple reaction mode scans) for both ofloxacin and the internal standard were 362.1 &gt; 318.1 and 332.1 &gt; 288.2, correspondingly.</p><sec><title>Statistical Analysis</title><p>Statistical analysis was performed using SPSS software ver. 28.0 (IBM, Armonk, NY, USA). All data were checked for normality using the Kolmogorov&#8211;Smirnov test. G-Power 3.1.9 (Universit&#228;t Kiel, Germany) was used to calculate the number of subjects that were required in each group to achieve a power level of 0.85. Initial descriptive statistics were undertaken. Data were presented as mean (&#177; standard deviation [SD]) when variables had a parametric distribution, and as median with ranges or absolute frequency and percentage when the distribution was non-parametric. A comparison of the measurements among the three groups was performed using the Kruskal&#8211;Wallis test with pairwise tests (two-sided) with Bonferroni correction. The Bonferroni correction was applied to avoid the risk of committing a type I error. To be more precise, the alpha level of 0.05 was corrected for multiple comparisons involving the three outcome measures, resulting in an alpha level of 0.017. The correlation of DED severity with the concentration of ofloxacin in the AqH was evaluated using the Spearman correlation coefficient (two-sided). All statistical tests were performed at a 5% level of significance.</p></sec></sec><sec sec-type="results" id="sec3-medicina-58-01031"><title>3. Results</title><p>Overall, 91 samples were analyzed by HPLC-MS/MS. The median AqH concentration of ofloxacin in group I (control cohort) was 199.9 ng/mL (range 92.2&#8211;442.8 ng/mL), whereas the media of the non-severe DED patient group II was 530.5 ng/mL (range 283.7&#8211;1004.9 ng/mL), and the median of the severe DED patient group III was 719.2 ng/mL (range 358.0&#8211;1512.4 ng/mL). The Kruskal&#8211;Wallis test showed a significant difference in the ofloxacin levels in the AqH among the three groups (<italic toggle="yes">p</italic> &lt; 0.001). Pairwise comparisons between groups (two-tailed, with a Bonferroni correction for multiple tests) resulted in a <italic toggle="yes">p</italic>-value of 0.001 when group I was compared to group II and group I was compared to group III, and <italic toggle="yes">p</italic>-values of 0.02 when group II was compared to group III (<xref rid="medicina-58-01031-f001" ref-type="fig">Figure 1</xref>).</p><p>Histograms of the concentration range of ofloxacin among each group are presented in <xref rid="medicina-58-01031-f002" ref-type="fig">Figure 2</xref>. The concentration range of ofloxacin and the percentage of patients with higher concentrations of ofloxacin in the AqH are augmenting gradually from group I to groups II and III. In group I, almost half of the patients (52.9%) corresponded with an ofloxacin concentration of less than 200 ng/mL, and a quarter (23.5%) of patients had a concentration between 200 ng/mL and 400 ng/mL. In group II, most patients (43.2%) were found to have a concentration between 400 ng/mL and 600 ng/mL, 24.3% between 200 and 400 ng/mL, and 13.5% between 600 ng/mL and 800 ng/mL. Group III exhibited a wider concentration range (1189.45 ng/mL) compared to group II (820.83 ng/mL) and group I (616.76 ng/mL). A peak percent of patients (27%) was found to be in the concentration range of 400 ng/mL to 600 ng/mL, followed by 21.6% of patients between 600 ng/mL and 800 ng/mL, 18.9% between 800 ng/mL and 1000 ng/mL, and 13.5% between 1000 ng/mL and 1200 ng/mL. The correlation study between the severity of DED across group I (cataract patients without DED), group II (mild/moderate DED), group III (severe DED), and the levels of ofloxacin revealed a strong positive correlation (r = 0.639, <italic toggle="yes">p</italic> &lt; 0.001).</p></sec><sec sec-type="discussion" id="sec4-medicina-58-01031"><title>4. Discussion</title><p>DED has globally evolved into a public health concern (it affects 6&#8211;34% of the global adult population), and it shows increasing prevalence worldwide [<xref rid="B26-medicina-58-01031" ref-type="bibr">26</xref>,<xref rid="B27-medicina-58-01031" ref-type="bibr">27</xref>]. It is recognized as being among the most common ocular conditions to seek treatment for [<xref rid="B28-medicina-58-01031" ref-type="bibr">28</xref>]. Moreover, DED is a common comorbidity in ocular diseases usually treated by topical drops, such as glaucoma, the most common cause of blindness, Sjogren&#8217;s syndrome, and graft versus host disease [<xref rid="B27-medicina-58-01031" ref-type="bibr">27</xref>,<xref rid="B29-medicina-58-01031" ref-type="bibr">29</xref>,<xref rid="B30-medicina-58-01031" ref-type="bibr">30</xref>]. Based on the disease&#8217;s prevalence, the effect of DED on the bioavailability of a topically applied drug in the A/C is plausible. None of the patients participating in the study developed post-operative endophthalmitis or any other ocular infection after cataract surgery.</p><p>To the best of our knowledge, the current study is the first to evaluate drug concentration in the AqH after topical instillation in patients with DED. Our results confirm that the disease&#8217;s severity positively correlates with drug concentration in the AqH (<xref rid="medicina-58-01031-f001" ref-type="fig">Figure 1</xref>). The median determined concentration values of ofloxacin augmented gradually from group I through to groups II and III (<xref rid="medicina-58-01031-f002" ref-type="fig">Figure 2</xref>). Compared to the control group, median levels of ofloxacin were increased almost two-fold in group II and increased three-fold in group III (<italic toggle="yes">p</italic> &lt; 0.001).</p><p>The topical application of antibiotics has considerable advantages. Confined systemic exposure leads to reduced risk of side effects that may result from administration through other common routes (per os, intravitreally), reduced risk of resistance, and the achievement of high concentrations on the ocular surface. Bouchard et al. reported that AqH aspiration within one hour of the last ofloxacin dose led to diminished AqH concentration in comparison to sampling afterward [<xref rid="B31-medicina-58-01031" ref-type="bibr">31</xref>]. Nevertheless, the cornea comprises a complicated barrier in intraocular penetration, mainly subject to its unique anatomy and the physicochemical properties of the antimicrobial agent. Drugs need to be both lipid- and water-soluble. Furthermore, elimination through the conjunctival vasculature and the tear drainage system rapidly reduces the tear concentration of the instilled drug, rendering the frequency of the applications a key element of bioavailability [<xref rid="B9-medicina-58-01031" ref-type="bibr">9</xref>,<xref rid="B10-medicina-58-01031" ref-type="bibr">10</xref>,<xref rid="B12-medicina-58-01031" ref-type="bibr">12</xref>,<xref rid="B32-medicina-58-01031" ref-type="bibr">32</xref>,<xref rid="B33-medicina-58-01031" ref-type="bibr">33</xref>].</p><p>Apart from these major ocular pharmacokinetic factors, drugs are usually administered under disease conditions that may differ from those normally present [<xref rid="B34-medicina-58-01031" ref-type="bibr">34</xref>]. The impact of inflammation has been extensively discussed, due to the physiological (e.g., lymphangiogenesis, increased vascular permeability) alterations and the possible damage inflicted on tissues [<xref rid="B35-medicina-58-01031" ref-type="bibr">35</xref>,<xref rid="B36-medicina-58-01031" ref-type="bibr">36</xref>,<xref rid="B37-medicina-58-01031" ref-type="bibr">37</xref>]. DED is considered an inflammatory disease, originating from tear hyperosmolarity and becoming amplified by the progression of numerous conditions (systemic diseases, such as Sjogren&#8217;s disease or rheumatoid arthritis; meibomian gland dysfunction; blepharitis; environmental factors, such as intense UV exposure or low humidity; toxic effects, such as preservatives of topical drugs; allergies; contact lens use; other concomitant eye inflammations, such as viral/bacterial conjunctivitis, ocular surgeries, hormonal imbalance, lid margin irregularities, or increased oxidative stress), resulting in the progressive destruction of the ocular surface and patient discomfort in accordance with disease progression. The disruption of corneal barriers may promote intraocular drug penetration, but conjunctival epithelium squamous metaplasia, in conjunction with the lymphangiogenesis in both the conjunctiva and cornea, may counteract this [<xref rid="B2-medicina-58-01031" ref-type="bibr">2</xref>,<xref rid="B3-medicina-58-01031" ref-type="bibr">3</xref>,<xref rid="B5-medicina-58-01031" ref-type="bibr">5</xref>,<xref rid="B38-medicina-58-01031" ref-type="bibr">38</xref>,<xref rid="B39-medicina-58-01031" ref-type="bibr">39</xref>,<xref rid="B40-medicina-58-01031" ref-type="bibr">40</xref>,<xref rid="B41-medicina-58-01031" ref-type="bibr">41</xref>,<xref rid="B42-medicina-58-01031" ref-type="bibr">42</xref>]. Animal in vivo studies, after the topical instillation of ofloxacin, confirmed higher intraocular bioavailability in inflamed eyes (mean AqH concentrations were significantly augmented), though this was due to intraocular infection rather than ocular surface inflammation [<xref rid="B34-medicina-58-01031" ref-type="bibr">34</xref>,<xref rid="B36-medicina-58-01031" ref-type="bibr">36</xref>,<xref rid="B37-medicina-58-01031" ref-type="bibr">37</xref>].</p><p>The ofloxacin concentrations determined in the AqH within the three cohorts of our study were compared with ofloxacin&#8217;s median MIC<sub>90</sub> towards the main pathogens causing endophthalmitis [<xref rid="B43-medicina-58-01031" ref-type="bibr">43</xref>,<xref rid="B44-medicina-58-01031" ref-type="bibr">44</xref>] (<xref rid="medicina-58-01031-t001" ref-type="table">Table 1</xref>). The median ofloxacin concentration of 199.9 ng/mL measured in patients without DED (group I) seems to be adequate only against <italic toggle="yes">gram-negative bacteria</italic>. However, in 23.5% of the group I patients, ofloxacin levels were measured in the AqH to be above the MIC<sub>90</sub> of <italic toggle="yes">coagulase-negative Staphylococci</italic> and <italic toggle="yes">Bacillus</italic> sp., whereas the ofloxacin levels were above the MIC<sub>90</sub> of <italic toggle="yes">Staphylococcus aureus</italic> in only 5.9% of the group I patients. In contrast, in patient groups II and III (with non-severe and severe DED, respectively), ofloxacin concentrations were above the MIC<sub>90</sub> for <italic toggle="yes">gram-negative bacteria</italic>. Further, in the majority of group II and III patients (78.4% and 94.6%, correspondingly), ofloxacin concentrations were found to be above the MIC<sub>90</sub> of <italic toggle="yes">coagulase-negative Staphylococci</italic> and <italic toggle="yes">Bacillus</italic> sp. In 27.0% and 54.1% of patients in groups II and III, respectively, levels of ofloxacin were found to be above the MIC<sub>90</sub> of <italic toggle="yes">S. aureus</italic>. A noteworthy finding is that 2.7% of the group III patients showed ofloxacin levels that were effective against <italic toggle="yes">&#946;-hemolytic Streptococcus</italic>. None of the DED or no-DED patients had ofloxacin levels that measured above the MIC<sub>90</sub> against <italic toggle="yes">Enterococci</italic> sp., <italic toggle="yes">Streptococcus viridans,</italic> or <italic toggle="yes">Streptococcus pneumoniae</italic>. The current topical ofloxacin instillation scheme might be inefficient in the prevention of post-operative endophthalmitis caused by a considerable number of common endophthalmitis pathogens.</p><p>The Current study with DED patients confirms the positive impact of inflammation in ocular therapeutics, as it may enhance the bioavailability of topical formulations, which is linked to more effective treatment of ocular diseases. This has also been shown in cases of other ocular inflammatory diseases (diabetes [<xref rid="B45-medicina-58-01031" ref-type="bibr">45</xref>], proliferative vitreoretinopathy, and penetrating eye injury with an intraocular foreign body [<xref rid="B46-medicina-58-01031" ref-type="bibr">46</xref>]). In order to evaluate the impact of ocular surface inflammation on ocular pharmacokinetics after topical drop instillation, the steady state and maximum concentration of every drug should be determined by implementing several different time points of sample collection.</p></sec><sec sec-type="conclusions" id="sec5-medicina-58-01031"><title>5. Conclusions</title><p>According to the finding of the current study, ofloxacin concentration in the A/C after topical drop instillation is affected by the degree of ocular surface inflammation in patients suffering from DED. Further studies are needed to confirm the impact of DED on ocular pharmacokinetics, considering the high prevalence of the disease.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>K.K. conceptualization, methodology, investigation, writing&#8212;original draft preparation, visualization; M.A.E.M. methodology, investigation, writing&#8212;original draft preparation; D.P. formal analysis; P.P. and G.D.P. methodology, validation, supervision; G.B.S. resources, writing&#8212;review and editing, validation, supervision; C.D.G. methodology, validation, formal analysis, investigation, resources, writing&#8212;review and editing, supervision, project administration. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of the University of Patras for human research (protocol code 1094 and date of approval 31 December 2018) for studies involving humans.</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are available upon reasonable request to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-medicina-58-01031"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nelson</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Craig</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Akpek</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Azar</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Belmonte</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bron</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Clayton</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Dogru</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dua</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Foulks</surname><given-names>G.N.</given-names></name><etal/></person-group><article-title>TFOS DEWS II Introduction</article-title><source>Ocul. Surf.</source><year>2017</year><volume>15</volume><fpage>269</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1016/j.jtos.2017.05.005</pub-id><pub-id pub-id-type="pmid">28736334</pub-id></element-citation></ref><ref id="B2-medicina-58-01031"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganesalingam</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sherwin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Craig</surname><given-names>J.P.</given-names></name></person-group><article-title>Molecular Evidence for the Role of Inflammation in Dry Eye Disease</article-title><source>Clin. Exp. Optom.</source><year>2019</year><volume>102</volume><fpage>446</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1111/cxo.12849</pub-id><pub-id pub-id-type="pmid">30630216</pub-id></element-citation></ref><ref id="B3-medicina-58-01031"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Periman</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Saban</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Neri</surname><given-names>P.</given-names></name></person-group><article-title>The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options</article-title><source>J. Ocul. Pharmacol. Ther.</source><year>2020</year><volume>36</volume><fpage>137</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1089/jop.2019.0060</pub-id><pub-id pub-id-type="pmid">32175799</pub-id><pub-id pub-id-type="pmcid">PMC7175622</pub-id></element-citation></ref><ref id="B4-medicina-58-01031"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsubota</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pflugfelder</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Baudouin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Messmer</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Kruse</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Carreno-Galeano</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Rolando</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Defining Dry Eye from a Clinical Perspective</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>9271</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21239271</pub-id><pub-id pub-id-type="pmid">33291796</pub-id><pub-id pub-id-type="pmcid">PMC7730816</pub-id></element-citation></ref><ref id="B5-medicina-58-01031"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perez</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Stern</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Pflugfelder</surname><given-names>S.C.</given-names></name></person-group><article-title>Inflammatory Basis for Dry Eye Disease Flares</article-title><source>Exp. Eye Res.</source><year>2020</year><volume>201</volume><fpage>108294</fpage><pub-id pub-id-type="doi">10.1016/j.exer.2020.108294</pub-id><pub-id pub-id-type="pmid">33039458</pub-id><pub-id pub-id-type="pmcid">PMC7736538</pub-id></element-citation></ref><ref id="B6-medicina-58-01031"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nair</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>D&#8217;Souza</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shetty</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ahuja</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kundu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Khamar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dadachanji</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Paritekar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dickman</surname><given-names>M.M.</given-names></name><etal/></person-group><article-title>Altered Ocular Surface Immune Cell Profile in Patients with Dry Eye Disease</article-title><source>Ocul. Surf.</source><year>2021</year><volume>21</volume><fpage>96</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.jtos.2021.04.002</pub-id><pub-id pub-id-type="pmid">33862224</pub-id></element-citation></ref><ref id="B7-medicina-58-01031"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akpek</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Amescua</surname><given-names>G.</given-names></name><name name-style="western"><surname>Farid</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garcia-Ferrer</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rhee</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Varu</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Musch</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Mah</surname><given-names>F.S.</given-names></name></person-group><article-title>Dry Eye Syndrome Preferred Practice Pattern<sup>&#174;</sup></article-title><source>Ophthalmology</source><year>2019</year><volume>126</volume><fpage>286</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2018.10.023</pub-id><pub-id pub-id-type="pmid">30366798</pub-id></element-citation></ref><ref id="B8-medicina-58-01031"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srinivasarao</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Lohiya</surname><given-names>G.</given-names></name><name name-style="western"><surname>Katti</surname><given-names>D.S.</given-names></name></person-group><article-title>Fundamentals, Challenges, and Nanomedicine-based Solutions for Ocular Diseases</article-title><source>WIREs Nanomed. Nanobiotechnol.</source><year>2019</year><volume>11</volume><fpage>e1548</fpage><pub-id pub-id-type="doi">10.1002/wnan.1548</pub-id><pub-id pub-id-type="pmid">30506871</pub-id></element-citation></ref><ref id="B9-medicina-58-01031"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>V.H.L.</given-names></name></person-group><article-title>Mechanisms and Facilitation of Corneal Drug Penetration</article-title><source>J. Control. Release</source><year>1990</year><volume>11</volume><fpage>79</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/0168-3659(90)90122-A</pub-id></element-citation></ref><ref id="B10-medicina-58-01031"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suri</surname><given-names>R.</given-names></name><name name-style="western"><surname>Beg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kohli</surname><given-names>K.</given-names></name></person-group><article-title>Target Strategies for Drug Delivery Bypassing Ocular Barriers</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2020</year><volume>55</volume><fpage>101389</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2019.101389</pub-id></element-citation></ref><ref id="B11-medicina-58-01031"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gote</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sikder</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sicotte</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pal</surname><given-names>D.</given-names></name></person-group><article-title>Ocular Drug Delivery: Present Innovations and Future Challenges</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2019</year><volume>370</volume><fpage>602</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1124/jpet.119.256933</pub-id><pub-id pub-id-type="pmid">31072813</pub-id></element-citation></ref><ref id="B12-medicina-58-01031"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agrahari</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mandal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Agrahari</surname><given-names>V.</given-names></name><name name-style="western"><surname>Trinh</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ray</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hadji</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mitra</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pal</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mitra</surname><given-names>A.K.</given-names></name></person-group><article-title>A Comprehensive Insight on Ocular Pharmacokinetics</article-title><source>Drug Deliv. Transl. Res.</source><year>2016</year><volume>6</volume><fpage>735</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1007/s13346-016-0339-2</pub-id><pub-id pub-id-type="pmid">27798766</pub-id><pub-id pub-id-type="pmcid">PMC5319401</pub-id></element-citation></ref><ref id="B13-medicina-58-01031"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayakawa</surname><given-names>I.</given-names></name><name name-style="western"><surname>Atarashi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yokohama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Imamura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sakano</surname><given-names>K.</given-names></name><name name-style="western"><surname>Furukawa</surname><given-names>M.</given-names></name></person-group><article-title>Synthesis and Antibacterial Activities of Optically Active Ofloxacin</article-title><source>Antimicrob. Agents Chemother.</source><year>1986</year><volume>29</volume><fpage>163</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1128/AAC.29.1.163</pub-id><pub-id pub-id-type="pmid">3460520</pub-id><pub-id pub-id-type="pmcid">PMC180386</pub-id></element-citation></ref><ref id="B14-medicina-58-01031"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gower</surname><given-names>E.W.</given-names></name><name name-style="western"><surname>Lindsley</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tulenko</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Nanji</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Leyngold</surname><given-names>I.</given-names></name><name name-style="western"><surname>McDonnell</surname><given-names>P.J.</given-names></name></person-group><article-title>Perioperative Antibiotics for Prevention of Acute Endophthalmitis after Cataract Surgery</article-title><source>Cochrane Database Syst. Rev.</source><year>2017</year><volume>2</volume><fpage>CD006364</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD006364.pub3</pub-id><pub-id pub-id-type="pmid">28192644</pub-id><pub-id pub-id-type="pmcid">PMC5375161</pub-id></element-citation></ref><ref id="B15-medicina-58-01031"><label>15.</label><element-citation publication-type="gov"><article-title>PubChem Compound Summary for CID 4583, Ofloxacin</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/Ofloxacin" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/compound/Ofloxacin</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-12-15">(accessed on 15 December 2021)</date-in-citation></element-citation></ref><ref id="B16-medicina-58-01031"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abelson</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Udell</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Weston</surname><given-names>J.H.</given-names></name></person-group><article-title>Normal Human Tear PH by Direct Measurement</article-title><source>Arch. Ophthalmol. (Chic. IL. 1960)</source><year>1981</year><volume>99</volume><fpage>301</fpage><pub-id pub-id-type="doi">10.1001/archopht.1981.03930010303017</pub-id><pub-id pub-id-type="pmid">7469869</pub-id></element-citation></ref><ref id="B17-medicina-58-01031"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fair</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Tor</surname><given-names>Y.</given-names></name></person-group><article-title>Antibiotics and Bacterial Resistance in the 21st Century</article-title><source>Perspect. Medicin. Chem.</source><year>2014</year><volume>6</volume><fpage>25</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.4137/PMC.S14459</pub-id><pub-id pub-id-type="pmid">25232278</pub-id><pub-id pub-id-type="pmcid">PMC4159373</pub-id></element-citation></ref><ref id="B18-medicina-58-01031"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kagkelaris</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Makri</surname><given-names>O.E.</given-names></name><name name-style="western"><surname>Georgakopoulos</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Panayiotakopoulos</surname><given-names>G.D.</given-names></name></person-group><article-title>An Eye for Azithromycin: Review of the Literature</article-title><source>Ther. Adv. Ophthalmol.</source><year>2018</year><volume>10</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1177/2515841418783622</pub-id><pub-id pub-id-type="pmcid">PMC6066808</pub-id><pub-id pub-id-type="pmid">30083656</pub-id></element-citation></ref><ref id="B19-medicina-58-01031"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mah</surname><given-names>F.S.</given-names></name></person-group><article-title>Fourth-Generation Fluoroquinolones: New Topical Agents in the War on Ocular Bacterial Infections</article-title><source>Curr. Opin. Ophthalmol.</source><year>2004</year><volume>15</volume><fpage>316</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1097/00055735-200408000-00007</pub-id><pub-id pub-id-type="pmid">15232471</pub-id></element-citation></ref><ref id="B20-medicina-58-01031"><label>20.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Santos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Altamirano-Vallejo</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Navarro-Partida</surname><given-names>J.</given-names></name><name name-style="western"><surname>la Rosa</surname><given-names>A.G.-D.</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>H.J.</given-names></name></person-group><article-title>Breaking down the Barrier: Topical Liposomes as Nanocarriers for Drug Delivery into the Posterior Segment of the Eyeball</article-title><source>Role of Novel Drug Delivery Vehicles in Nanobiomedicine</source><edition>1st ed.</edition><person-group person-group-type="editor"><name name-style="western"><surname>Tyagi</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Garg</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bisen</surname><given-names>P.S.</given-names></name></person-group><publisher-name>IntechOpen</publisher-name><publisher-loc>London, UK</publisher-loc><year>2020</year><fpage>23</fpage><lpage>58</lpage><isbn>978-1-78923-986-7</isbn></element-citation></ref><ref id="B21-medicina-58-01031"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baudouin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aragona</surname><given-names>P.</given-names></name><name name-style="western"><surname>Van Setten</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rolando</surname><given-names>M.</given-names></name><name name-style="western"><surname>Irke&#231;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ben&#237;tez del Castillo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Geerling</surname><given-names>G.</given-names></name><name name-style="western"><surname>Labetoulle</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bonini</surname><given-names>S.</given-names></name></person-group><article-title>Diagnosing the Severity of Dry Eye: A Clear and Practical Algorithm</article-title><source>Br. J. Ophthalmol.</source><year>2014</year><volume>98</volume><fpage>1168</fpage><lpage>1176</lpage><pub-id pub-id-type="doi">10.1136/bjophthalmol-2013-304619</pub-id><pub-id pub-id-type="pmid">24627252</pub-id><pub-id pub-id-type="pmcid">PMC4145432</pub-id></element-citation></ref><ref id="B22-medicina-58-01031"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Starr</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Farid</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beckman</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Yeu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>J.A.P.</given-names></name><name name-style="western"><surname>Ayers</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Berdahl</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Holland</surname><given-names>E.J.</given-names></name><etal/></person-group><article-title>An Algorithm for the Preoperative Diagnosis and Treatment of Ocular Surface Disorders</article-title><source>J. Cataract Refract. Surg.</source><year>2019</year><volume>45</volume><fpage>669</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1016/j.jcrs.2019.03.023</pub-id><pub-id pub-id-type="pmid">31030780</pub-id></element-citation></ref><ref id="B23-medicina-58-01031"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El Mubarak</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Kagkelaris</surname><given-names>K.</given-names></name><name name-style="western"><surname>Panayiotakopoulos</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Thomopoulou</surname><given-names>V.</given-names></name><name name-style="western"><surname>Georgakopoulos</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Sivolapenko</surname><given-names>G.B.</given-names></name></person-group><article-title>Quantification of Ofloxacin in Human Aqueous Humour of the Eye by LC-MS/MS</article-title><source>J. Anal. Bioanal. Tech.</source><year>2022</year><volume>13</volume><fpage>435</fpage><pub-id pub-id-type="doi">10.4172/2155-9872.1000435</pub-id></element-citation></ref><ref id="B24-medicina-58-01031"><label>24.</label><element-citation publication-type="webpage"><article-title>EMEA Guideline on Bioanalytical Method Validation</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf" ext-link-type="uri">https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-12-15">(accessed on 15 December 2021)</date-in-citation></element-citation></ref><ref id="B25-medicina-58-01031"><label>25.</label><element-citation publication-type="gov"><article-title>FDA &amp; CDER Bioanalytical Method Validation Guidance for Industry Biopharmaceutics Contains Nonbinding Recommendations</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry" ext-link-type="uri">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-12-15">(accessed on 15 December 2021)</date-in-citation></element-citation></ref><ref id="B26-medicina-58-01031"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stapleton</surname><given-names>F.</given-names></name><name name-style="western"><surname>Alves</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bunya</surname><given-names>V.Y.</given-names></name><name name-style="western"><surname>Jalbert</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lekhanont</surname><given-names>K.</given-names></name><name name-style="western"><surname>Malet</surname><given-names>F.</given-names></name><name name-style="western"><surname>Na</surname><given-names>K.-S.</given-names></name><name name-style="western"><surname>Schaumberg</surname><given-names>D.</given-names></name><name name-style="western"><surname>Uchino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vehof</surname><given-names>J.</given-names></name><etal/></person-group><article-title>TFOS DEWS II Epidemiology Report</article-title><source>Ocul. Surf.</source><year>2017</year><volume>15</volume><fpage>334</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1016/j.jtos.2017.05.003</pub-id><pub-id pub-id-type="pmid">28736337</pub-id></element-citation></ref><ref id="B27-medicina-58-01031"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clayton</surname><given-names>J.A.</given-names></name></person-group><article-title>Dry Eye</article-title><source>N. Engl. J. Med.</source><year>2018</year><volume>378</volume><fpage>2212</fpage><lpage>2223</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1407936</pub-id><pub-id pub-id-type="pmid">29874529</pub-id></element-citation></ref><ref id="B28-medicina-58-01031"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bradley</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>&#214;zer Stillman</surname><given-names>I.</given-names></name><name name-style="western"><surname>Pivneva</surname><given-names>I.</given-names></name><name name-style="western"><surname>Guerin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Dana</surname><given-names>R.</given-names></name></person-group><article-title>Dry Eye Disease Ranking among Common Reasons for Seeking Eye Care in a Large US Claims Database</article-title><source>Clin. Ophthalmol.</source><year>2019</year><volume>13</volume><fpage>225</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.2147/OPTH.S188314</pub-id><pub-id pub-id-type="pmid">30774303</pub-id><pub-id pub-id-type="pmcid">PMC6362914</pub-id></element-citation></ref><ref id="B29-medicina-58-01031"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Derby</surname><given-names>E.</given-names></name><name name-style="western"><surname>Holland</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Khatana</surname><given-names>A.K.</given-names></name></person-group><article-title>Incidence and Prevalence of Glaucoma in Severe Ocular Surface Disease</article-title><source>Cornea</source><year>2006</year><volume>25</volume><fpage>530</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1097/01.ico.0000220776.93852.d9</pub-id><pub-id pub-id-type="pmid">16783140</pub-id></element-citation></ref><ref id="B30-medicina-58-01031"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baudouin</surname><given-names>C.</given-names></name></person-group><article-title>Side Effects of Antiglaucomatous Drugs on the Ocular Surface</article-title><source>Curr. Opin. Ophthalmol.</source><year>1996</year><volume>7</volume><fpage>80</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1097/00055735-199604000-00014</pub-id><pub-id pub-id-type="pmid">10163327</pub-id></element-citation></ref><ref id="B31-medicina-58-01031"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bouchard</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>King</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>J.M.</given-names></name></person-group><article-title>The Kinetics of Anterior Chamber Ofloxacin Penetration</article-title><source>Cornea</source><year>1996</year><volume>15</volume><fpage>72</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1097/00003226-199601000-00013</pub-id><pub-id pub-id-type="pmid">8907384</pub-id></element-citation></ref><ref id="B32-medicina-58-01031"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadiq</surname><given-names>M.</given-names></name></person-group><article-title>Factors Affecting Corneal Penetration of Drugs</article-title><source>Al-Shifa J. Ophthalmol.</source><year>2016</year><volume>12</volume><fpage>123</fpage><lpage>124</lpage></element-citation></ref><ref id="B33-medicina-58-01031"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Javadzadeh</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Omidi</surname><given-names>Y.</given-names></name></person-group><article-title>Ocular Novel Drug Delivery: Impacts of Membranes and Barriers</article-title><source>Expert Opin. Drug Deliv.</source><year>2008</year><volume>5</volume><fpage>567</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1517/17425247.5.5.567</pub-id><pub-id pub-id-type="pmid">18491982</pub-id></element-citation></ref><ref id="B34-medicina-58-01031"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ueda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ohtori</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tojo</surname><given-names>K.</given-names></name></person-group><article-title>Effects of Pathological Conditions on Ocular Pharmacokinetics of Antimicrobial Drugs</article-title><source>Chem. Pharm. Bull.</source><year>2010</year><volume>58</volume><fpage>1301</fpage><lpage>1305</lpage><pub-id pub-id-type="doi">10.1248/cpb.58.1301</pub-id><pub-id pub-id-type="pmid">20930394</pub-id></element-citation></ref><ref id="B35-medicina-58-01031"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gatti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Panozzo</surname><given-names>G.</given-names></name></person-group><article-title>Effect of Inflammation on Intraocular Penetration of Intravenous Ofloxacin in Albino Rabbits</article-title><source>Antimicrob. Agents Chemother.</source><year>1995</year><volume>39</volume><fpage>549</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1128/AAC.39.2.549</pub-id><pub-id pub-id-type="pmid">7726531</pub-id><pub-id pub-id-type="pmcid">PMC162578</pub-id></element-citation></ref><ref id="B36-medicina-58-01031"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#214;zt&#252;rk</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kortunay</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kurt</surname><given-names>E.</given-names></name><name name-style="western"><surname>Inan</surname><given-names>&#220;.&#220;.</given-names></name><name name-style="western"><surname>Ilker</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Basci</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bozkurt</surname><given-names>A.</given-names></name></person-group><article-title>The Effect of Long-Term Use and Inflammation on the Ocular Penetration of Topical Ofloxacin</article-title><source>Curr. Eye Res.</source><year>1999</year><volume>19</volume><fpage>461</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1076/ceyr.19.6.461.5277</pub-id><pub-id pub-id-type="pmid">10550786</pub-id></element-citation></ref><ref id="B37-medicina-58-01031"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#214;zt&#252;rk</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kurt</surname><given-names>E.</given-names></name><name name-style="western"><surname>Inan</surname><given-names>&#220;.&#220;.</given-names></name><name name-style="western"><surname>Kortunay</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ilker</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Ba&#351;ci</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Bozkurt</surname><given-names>A.</given-names></name></person-group><article-title>Penetration of Topical and Oral Ofloxacin into the Aqueous and Vitreous Humor of Inflamed Rabbit Eyes</article-title><source>Int. J. Pharm.</source><year>2000</year><volume>204</volume><fpage>91</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/S0378-5173(00)00482-8</pub-id><pub-id pub-id-type="pmid">11011990</pub-id></element-citation></ref><ref id="B38-medicina-58-01031"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baudouin</surname><given-names>C.</given-names></name></person-group><article-title>The Vicious Circle in Dry Eye Syndrome: A Mechanistic Approach</article-title><source>J. Fr. Ophtalmol.</source><year>2007</year><volume>30</volume><fpage>239</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1016/S0181-5512(07)89584-2</pub-id><pub-id pub-id-type="pmid">17417148</pub-id></element-citation></ref><ref id="B39-medicina-58-01031"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chennakesavalu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Somala</surname><given-names>S.R.R.</given-names></name><name name-style="western"><surname>Dommaraju</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Peesapati</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rosenblatt</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Azar</surname><given-names>D.T.</given-names></name></person-group><article-title>Corneal Lymphangiogenesis as a Potential Target in Dry Eye Disease-a Systematic Review</article-title><source>Surv. Ophthalmol.</source><year>2021</year><volume>66</volume><fpage>960</fpage><lpage>976</lpage><pub-id pub-id-type="doi">10.1016/j.survophthal.2021.03.007</pub-id><pub-id pub-id-type="pmid">33811911</pub-id><pub-id pub-id-type="pmcid">PMC9991079</pub-id></element-citation></ref><ref id="B40-medicina-58-01031"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>L.</given-names></name></person-group><article-title>Dry Eye Disease and Oxidative Stress</article-title><source>Acta Ophthalmol.</source><year>2018</year><volume>96</volume><fpage>e412</fpage><lpage>e420</lpage><pub-id pub-id-type="doi">10.1111/aos.13526</pub-id><pub-id pub-id-type="pmid">28834388</pub-id></element-citation></ref><ref id="B41-medicina-58-01031"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baudouin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Irke&#231;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Messmer</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Ben&#237;tez-del-Castillo</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Bonini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Figueiredo</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Geerling</surname><given-names>G.</given-names></name><name name-style="western"><surname>Labetoulle</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lemp</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rolando</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Clinical Impact of Inflammation in Dry Eye Disease: Proceedings of the ODISSEY Group Meeting</article-title><source>Acta Ophthalmol.</source><year>2018</year><volume>96</volume><fpage>111</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1111/aos.13436</pub-id><pub-id pub-id-type="pmid">28390092</pub-id><pub-id pub-id-type="pmcid">PMC5836968</pub-id></element-citation></ref><ref id="B42-medicina-58-01031"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stevenson</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chauhan</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Dana</surname><given-names>R.</given-names></name></person-group><article-title>Dry Eye Disease: An Immune-Mediated Ocular Surface Disorder</article-title><source>Arch. Ophthalmol.</source><year>2012</year><volume>130</volume><fpage>90</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1001/archophthalmol.2011.364</pub-id><pub-id pub-id-type="pmid">22232476</pub-id><pub-id pub-id-type="pmcid">PMC3677724</pub-id></element-citation></ref><ref id="B43-medicina-58-01031"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mather</surname><given-names>R.</given-names></name><name name-style="western"><surname>Karenchak</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Romanowski</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Kowalski</surname><given-names>R.P.</given-names></name></person-group><article-title>Fourth Generation Fluoroquinolones: New Weapons in the Arsenal of Ophthalmic Antibiotics</article-title><source>Am. J. Ophthalmol.</source><year>2002</year><volume>133</volume><fpage>463</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1016/S0002-9394(02)01334-X</pub-id><pub-id pub-id-type="pmid">11931779</pub-id></element-citation></ref><ref id="B44-medicina-58-01031"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lemley</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Han</surname><given-names>D.P.</given-names></name></person-group><article-title>Endophthalmitis: A Review of Current Evaluation and Management</article-title><source>Retina</source><year>2007</year><volume>27</volume><fpage>662</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1097/IAE.0b013e3180323f96</pub-id><pub-id pub-id-type="pmid">17621174</pub-id></element-citation></ref><ref id="B45-medicina-58-01031"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plotas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Anastasopoulos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Makri</surname><given-names>O.E.</given-names></name><name name-style="western"><surname>Leotsinidis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Georgakopoulos</surname><given-names>C.D.</given-names></name></person-group><article-title>A UPLC-MS Method for the Determination of Ofloxacin Concentrations in Aqueous Humor</article-title><source>Anal. Chem. Insights</source><year>2014</year><volume>9</volume><fpage>27</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.4137/ACI.S13857</pub-id><pub-id pub-id-type="pmid">24868142</pub-id><pub-id pub-id-type="pmcid">PMC4022703</pub-id></element-citation></ref><ref id="B46-medicina-58-01031"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cekic</surname><given-names>O.</given-names></name><name name-style="western"><surname>Batman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yasar</surname><given-names>&#220;.</given-names></name><name name-style="western"><surname>Basci</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Bozkurt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kayaalp</surname><given-names>S.O.</given-names></name></person-group><article-title>Penetration of Ofloxacin in Human Aqueous and Vitreous Humors Following Oral and Topical Administration</article-title><source>Retina</source><year>1998</year><volume>18</volume><fpage>521</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1097/00006982-199806000-00005</pub-id><pub-id pub-id-type="pmid">9869460</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="medicina-58-01031-f001" orientation="portrait"><label>Figure 1</label><caption><p>Median ofloxacin concentrations (ng/mL) in the AqH. Error bars represent the interquartile range. <italic toggle="yes">p</italic> &lt; 0.001 (Kruskal&#8211;Wallis test) differences between group I and group II and groups I and III (pairwise comparisons). <italic toggle="yes">p</italic> = 0.02 differences between groups II and III (pairwise comparisons).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medicina-58-01031-g001.jpg"/></fig><fig position="float" id="medicina-58-01031-f002" orientation="portrait"><label>Figure 2</label><caption><p>Histograms showing the concentration (ng/mL) range of ofloxacin in the AqH after topical drop instillation by the percentage of patients in each group. Group I, cataract patients without DED; group II, cataract patients with non-severe DED; group III, cataract patients with severe DED.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medicina-58-01031-g002.jpg"/></fig><table-wrap position="float" id="medicina-58-01031-t001" orientation="portrait"><object-id pub-id-type="pii">medicina-58-01031-t001_Table 1</object-id><label>Table 1</label><caption><p>Median minimum inhibitory concentrations (MIC<sub>90</sub>) of ofloxacin in the AqH for common endophthalmitis pathogens [<xref rid="B43-medicina-58-01031" ref-type="bibr">43</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Organism</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ofloxacin MIC<sub>90</sub> (ng/mL)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Streptococcus pneumoniae</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Streptococcus viridans</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Enterococci species</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2000</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">&#946;-hemolytic Streptococcus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1500</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcus aureus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">630</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Bacillus species</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">380</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">coagulase-negative Staphylococci</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">380</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">gram-negative bacteria</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">190</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>